433 related articles for article (PubMed ID: 27354763)
1. Molecular mechanisms of cisplatin resistance in cervical cancer.
Zhu H; Luo H; Zhang W; Shen Z; Hu X; Zhu X
Drug Des Devel Ther; 2016; 10():1885-95. PubMed ID: 27354763
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin in advanced cancer of the cervix: an update.
Alberts DS; Garcia D; Mason-Liddil N
Semin Oncol; 1991 Feb; 18(1 Suppl 3):11-24. PubMed ID: 2003224
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
4. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
Takekuma M; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Gynecol Oncol; 2015 Jul; 26(3):185-92. PubMed ID: 26197856
[TBL] [Abstract][Full Text] [Related]
5. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
Torii Y; Kato R; Minami Y; Hasegawa K; Fujii T; Udagawa Y
Anticancer Res; 2014 Jan; 34(1):107-15. PubMed ID: 24403450
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for recurrent cervical cancer.
Cadron I; Van Gorp T; Amant F; Leunen K; Neven P; Vergote I
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S113-8. PubMed ID: 17804044
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Dunst J; Haensgen G
Strahlenther Onkol; 2001 Dec; 177(12):635-40. PubMed ID: 11789401
[TBL] [Abstract][Full Text] [Related]
10. Management of metastatic cervical cancer: review of the literature.
Long HJ
J Clin Oncol; 2007 Jul; 25(20):2966-74. PubMed ID: 17617528
[TBL] [Abstract][Full Text] [Related]
11. A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Manci N; Marchetti C; Di Tucci C; Giorgini M; Esposito F; Palaia I; Musella A; Perniola G; Carrone A; Benedetti Panici P
Gynecol Oncol; 2011 Aug; 122(2):285-90. PubMed ID: 21555147
[TBL] [Abstract][Full Text] [Related]
12. Advances in cervical cancer pharmacotherapies.
Markman M
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):219-23. PubMed ID: 24490716
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for recurrent and metastatic cervical cancer.
Tao X; Hu W; Ramirez PT; Kavanagh JJ
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
[TBL] [Abstract][Full Text] [Related]
15. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Miyamoto Y; Nakagawa S; Wada-Hiraike O; Seiki T; Tanikawa M; Hiraike H; Sone K; Nagasaka K; Oda K; Kawana K; Nakagawa K; Fujii T; Yano T; Kozuma S; Taketani Y
Oncol Rep; 2013 Jan; 29(1):51-7. PubMed ID: 23064281
[TBL] [Abstract][Full Text] [Related]
16. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
[TBL] [Abstract][Full Text] [Related]
17. Correlations of MicroRNA-21 Gene Polymorphisms With Chemosensitivity and Prognosis of Cervical Cancer.
Zhang J; Li YH; Liu HL; Zhang Y; Zhang QS; Li SZ
Am J Med Sci; 2018 Dec; 356(6):544-551. PubMed ID: 30447706
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance.
Leisching G; Loos B; Botha M; Engelbrecht AM
J Transl Med; 2015 Oct; 13():328. PubMed ID: 26474854
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin resistance in human cervical, ovarian and lung cancer cells.
Chen J; Solomides C; Parekh H; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1217-27. PubMed ID: 25894720
[TBL] [Abstract][Full Text] [Related]
20. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
